Literature DB >> 28671269

Src nuclear localization and its prognostic relevance in human osteosarcoma.

Enrica Urciuoli1,2, Ilenia Coletta1, Emanuele Rizzuto3, Rita De Vito4, Stefania Petrini5, Valentina D'Oria5, Marco Pezzullo6, Giuseppe Maria Milano7, Raffaele Cozza7, Franco Locatelli7,8, Barbara Peruzzi1.   

Abstract

Osteosarcoma is the most common malignant bone tumor in children and young adults. The identification of proteins which exhibit different subcellular localization in low- versus high-risk osteosarcoma can be instrumental to obtain prognostic information and to develop innovative therapeutic strategies. Beside the well-characterized membrane and cytoplasmic localization of Src protein, this study evaluated the prognostic relevance of its so-far unknown nuclear compartmentalization. We analyzed the subcellular distribution of total and activated (pY418) Src in a tissue microarray including 60 osteosarcoma samples. Immunohistochemical analyses revealed a variable pattern of Src expression and localization, ranging from negative to high-stained nuclei combined with a substantial cytoplasmic staining for total and activated forms. The analysis of Kaplan-Meier survival curves in relationship to the diverse permutations of cytoplasmic and nuclear staining suggested a correlation between Src subcellular localization and the overall survival (OS) of osteosarcoma patients. In order to explain this different subcellular localization, normal osteoblasts and three osteosarcoma cell lines were used to investigate the molecular mechanism. Once confirmed a variable Src localization also in these cell lines, we demonstrated a correlation between the N-myristoyltransferase enzymes expression and activity and the Src nuclear content. In conclusion, these results described a so-far unknown Src nuclear localization in osteosarcoma cells, suggesting that the combined detection of nuclear and cytoplasmic Src levels can be used as a prognostic marker for osteosarcoma patient survival. A correlation between the N-myristoyltransferase enzymes and the Src subcellular localization was described as well.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  NMTs; Src tyrosine-kinase; myristoylation; osteosarcoma; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28671269     DOI: 10.1002/jcp.26079

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  Manipulation of Focal Adhesion Signaling by Pathogenic Microbes.

Authors:  Korinn N Murphy; Amanda J Brinkworth
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

Review 2.  Cross-Talk between Wnt Signaling and Src Tyrosine Kinase.

Authors:  Jung Ki Min; Hwee-Seon Park; Yoon-Beom Lee; Jae-Gyu Kim; Jong-Il Kim; Jae-Bong Park
Journal:  Biomedicines       Date:  2022-05-11

Review 3.  Advancing therapy for osteosarcoma.

Authors:  Jonathan Gill; Richard Gorlick
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

Review 4.  Involvement of the FAK Network in Pathologies Related to Altered Mechanotransduction.

Authors:  Enrica Urciuoli; Barbara Peruzzi
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

Review 5.  Future Directions in the Treatment of Osteosarcoma.

Authors:  Alannah Smrke; Peter M Anderson; Ashish Gulia; Spyridon Gennatas; Paul H Huang; Robin L Jones
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600

Review 6.  Nuclear Functions of the Tyrosine Kinase Src.

Authors:  Giulia Bagnato; Martina Leopizzi; Enrica Urciuoli; Barbara Peruzzi
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923

7.  Deep RNA sequencing reveals the dynamic regulation of miRNA, lncRNAs, and mRNAs in osteosarcoma tumorigenesis and pulmonary metastasis.

Authors:  Lin Xie; Zhihong Yao; Ya Zhang; Dongqi Li; Fengdi Hu; Yedan Liao; Ling Zhou; Yonghong Zhou; Zeyong Huang; Zewei He; Lei Han; Yihao Yang; Zuozhang Yang
Journal:  Cell Death Dis       Date:  2018-07-10       Impact factor: 8.469

8.  miR-210 promotes human osteosarcoma cell migration and invasion by targeting FGFRL1.

Authors:  Xiangjun Liu; Chengfeng Zhang; Cunhua Wang; Jianwei Sun; Deliang Wang; Yansheng Zhao; Xiaohui Xu
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 2.967

9.  Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.

Authors:  Kristin Baird; John Glod; Seth M Steinberg; Denise Reinke; Joseph G Pressey; Leo Mascarenhas; Noah Federman; Neyssa Marina; Sant Chawla; Joanne P Lagmay; John Goldberg; Mohammed Milhem; David M Loeb; James E Butrynski; Brian Turpin; Arthur Staddon; Sheri L Spunt; Robin L Jones; Eve T Rodler; Scott M Schuetze; Scott H Okuno; Lee Helman
Journal:  Sarcoma       Date:  2020-04-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.